The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study

BACKGROUND: Inhibition of CDK7, a potent transcription regulator, may bring new hope for treating pancreatic ductal adenocarcinoma (PDAC), which is featured by large genetic heterogeneity and abundant KRAS mutations. This investigation aimed at exploring the discrepant efficacies of THZ1, a small‐mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lei, Yang, Hui, Chen, Kaidi, Yuan, Jing, Li, Jie, Dai, Guanghai, Gu, Mancang, Shi, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689978/
https://www.ncbi.nlm.nih.gov/pubmed/38037549
http://dx.doi.org/10.1002/ctm2.1500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689978/
https://www.ncbi.nlm.nih.gov/pubmed/38037549
http://dx.doi.org/10.1002/ctm2.1500

Ejemplares similares